Tag: BRAF V600E

By Posted on Posted in Allelic Variant, Genetic Background, Genetic Predisposition, New Indication Approval, Personalized Medicine, Rare Diseases, Regulatory Announcement, Targeted Therapy, Thasso Post, Theragenomic Medicine Tagged with , , , , , , , , ,

Dezember 21, 2017 – Erdheim–Chester disease ((ECD), also known as Erdheim–Chester syndrome or polyostotic sclerosing histiocytosis) is a form of a bone marrow borne blood cancer. It is a rare disease characterized by the abnormal multiplication of a specific type …

Vemurafenib (Zelboraf) for BRAF V600E positive Erdheim-Chester Disease (ECD) Read more »

By Posted on Posted in New Drug Approval, Thasso Post, Theragenomic Medicine Tagged with , , , , , , , , , , , , , , ,

November 13, 2015 – The American Food and Drug Administration (FDA) just approved Cobimetinib (Cotellic) to be used in combination with Vemurafenib (Zelboraf) to treat advanced melanoma that has spread to other parts of the body or can’t be removed by …

Cobimetinib (Cotellic) is now approved as part of a combination treatment with Vemurafenib (Zelboraf) for advanced melanoma Read more »

By Posted on Posted in Allelische Variante, Keine Kategorie, Personalized Medicine, Pharmacogenetics, Thasso Post Tagged with , , , , , , , , , , , , ,

October 10, 2013 – Very recently, David Kerr, Professor of Cancer Medicine at University of Oxford, in the United Kingdom, and past President of the European Society for Medical Oncology, talked on Medscape (see the video here) about risk-benefit analyses …

Can We Identify Risk for Drug Toxicity? Read more »